61-75 of 188
Albuminuria Change and Finerenone's Effect on CV Outcomes
DataPulse: Focus on the Latest Updates on Non-Steroidal MRAs in Patients with Heart Failure (HFmrEF/HFpEF)Albuminuria Change and Finerenone's Effect on CV Outcomes
Finnian R. McCausland, MD
TILplus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Project Oncology®TILplus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
Novel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
Broadcast ReplayNovel Therapies in Managing Patients With Cardiovascular-Kidney-Metabolic Syndrome and Heart Failure
Riccardo Maria Inciardi, MD, PhD
Cristina Gavina, MD, PhD
Giuseppe Galati, MD
Optimizing C3G Management: The Power of Lifestyle Changes and Supportive Care
On the Frontlines of C3GOptimizing C3G Management: The Power of Lifestyle Changes and Supportive Care
Richard Lafayette, MD, FACP
Patient Counseling in C3GN: From Disease Education to Shared Decision-Making
On the Frontlines of C3GPatient Counseling in C3GN: From Disease Education to Shared Decision-Making
Gates B. Colbert, MD
Challenges in C3GN Care: Managing Relapsing and Treatment-Resistant Disease
On the Frontlines of C3GChallenges in C3GN Care: Managing Relapsing and Treatment-Resistant Disease
Gates B. Colbert, MD
- advertisement
Advancing C3G Care with the Approval of a Complement Factor B Inhibitor
On the Frontlines of C3GAdvancing C3G Care with the Approval of a Complement Factor B Inhibitor
Enhancing Lupus Nephritis Outcomes: The Potential Impact of Lower Glucocorticoid Doses
Living RheumEnhancing Lupus Nephritis Outcomes: The Potential Impact of Lower Glucocorticoid Doses
APOL1 and Chronic Kidney Disease: New Findings in African Populations
Clinician's RoundtableAPOL1 and Chronic Kidney Disease: New Findings in African Populations
Rasheed A. Gbadegesin, MD, MBBS
Diagnosing IgAN: The Importance of Early and Accurate Identification
Clinician's RoundtableDiagnosing IgAN: The Importance of Early and Accurate Identification
James Chevalier, MD
Investigating the Incidence of IgA Nephropathy Among Racial and Ethnic Groups
Clinician's RoundtableInvestigating the Incidence of IgA Nephropathy Among Racial and Ethnic Groups
John Sim, MD
IgAN Explained: Key Differences from Other Kidney Conditions
Clinician's RoundtableIgAN Explained: Key Differences from Other Kidney Conditions
Mohamed Ibrahim, MB, BCh
- advertisement
Measuring IgAN Risk: Genetic, Environmental, and Systemic Factors
Clinician's RoundtableMeasuring IgAN Risk: Genetic, Environmental, and Systemic Factors
Mohamed Ibrahim, MB, BCh
Deciphering IgA Nephropathy: Insights into the Diagnostic Process
On the Frontlines of IgA NephropathyDeciphering IgA Nephropathy: Insights into the Diagnostic Process
Gates B. Colbert, MD
The Diagnostic Journey of IgA Nephropathy: Identifying Key Obstacles
On the Frontlines of IgA NephropathyThe Diagnostic Journey of IgA Nephropathy: Identifying Key Obstacles
Gates B. Colbert, MD
